Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hermes, Barbara; Schuette, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp J.; Al-Batran, Salah-Eddin; Lindner, Lars H.; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Kallio, Raija; Jaakkola, Panu; Junnila, Jouni; Alvegard, Thor; Reichardt, Peter

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Author:

Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hermes, Barbara; Schuette, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp J.; Al-Batran, Salah-Eddin; Lindner, Lars H.; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Kallio, Raija; Jaakkola, Panu; Junnila, Jouni; Alvegard, Thor; Reichardt, Peter

Tübinger Autor(en):

Hermes, Barbara

Published in:

Jama Oncology (2020), Bd. 6, H. 8, S. 1241-1246

Verlagsangabe:

Amer Medical Assoc

Language:

English

Full text:

http://dx.doi.org/10.1001/jamaoncol.2020.2091

ISSN:

2374-2445